At the last check in the premarket trading session, AZN stock surged by 4.11% to $53.48 following quarterly results. AZN stock closed previous session at $51.37 to loss of -1.36%. The stock volume traded today at 11.15 million shares. While the average 3-month trading volume for the AZN stock has been 10.48 million. In the past year, AZN stock had surged by 1.28%. While in the past week, the AZN stock moved down by -2.54%.
Background of the AstraZeneca COVID vaccine maker
AstraZeneca PLC is a multinational pharmaceutical company that focuses on the designing, developing, discovering, manufacturing, and marketing prescription medicines. These prescription medicines are developed for a wide segment of medical areas and needs including neuroscience, oncology, respiratory, renal and metabolism, cardiovascular, infection, and gastroenterology. AZN stock markets these medicines worldwide.
AstraZeneca was formerly known as Zeneca Group PLC until April 1999. The company was founded in 1992 and is headquartered in United Kingdom, Cambridge.
The company is recently in the international spotlight due to the pandemic as it has started offering COVID-19 products which include FluMistQuadrivalent, Nexium, Vimovo, Moventig, Prilosec, Synagis, and Fluenz Tetra. The company’s main COVID-19 lead product is the COVID-19 Vaccine AstraZeneca which had successful trials declared on 23rd November 2020 with 70% efficacy.
The Anglo-Swedish drug-maker has released financial results of its vaccine’s sale performance
On 30th April 2021, AstraZeneca PLC announced that its COVID vaccine has delivered sales of $275 million or £198 million. This sales performance is better than the expected guidance for the first quarter result.
This financial results and updates related to AstraZeneca PLC’s COVID 19 vaccine’s distribution and sales performance has been given for the first time. The company has reported that it will not make profit from the AstraZeneca COVID 19 vaccine during the pandemic. The company had delivered approximately 68 million global doses. This allowed the revenue for the first three months of 2021 to be equal to $7.3 billion which is a 15% increase. The core earnings were expected to be $1.48, in actuality, the core earnings beat the analysis at $1.63 soaring 55%.
The company has re-adjusted the full-year guidance for its core earnings per share to an estimate of $4.75-$5. AstraZeneca reports that the profit after tax reached £1.56 billion jumping from £750 million. The sales in emerging markets were $43 million, while in Europe it was expectedly the highest $224 million and the rest of the world was $8 million.
So why is AstraZeneca facing legal repercussions from the EU commission?
The financial results are a contrast against the uninspiring earning release by GSK as well as the worsening situation of global pandemic.
However, the Anglo-Swedish drugmaker has been facing backlash and is embroiled in a legal clash with European Union over the delays in the deliveries of its vaccine along with the rare cases of blood clots with lowered blood platelets emerging. The Europe commission includes Netherlands, Denmark, Norway, Iceland, Bulgaria, and recently joined Ireland in the legal case due to faltering over the promises and commitments made by AstraZeneca.
The chief executive of AstraZeneca, Soriot has defended the company by saying that it has delivered to its maximum capacity and as many doses as possible, however, he added that there was disappointment over not delivering more, but it would not deter them from committing to increasing the supply as much as possible. 300 million dosages of the drug have been made possible and available in 165 countries which included the recently COVID-devastated India. 90% of the COVID vaccine available in India is AstraZeneca.